Fred Alger Management LLC Makes New Investment in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Fred Alger Management LLC acquired a new position in Kiniksa Pharmaceuticals, purchasing 21,823 shares valued at approximately $485,000.
• Several analysts have upgraded Kiniksa's stock ratings, with Jefferies increasing the price target from $45.00 to $54.00 and six analysts rating the stock as "Buy".
• Insider trading activity shows notable sales, with the chief accounting officer selling 11,000 shares recently, which represents a 22.44% decrease in their ownership of the company.

Fred Alger Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 21,823 shares of the company's stock, valued at approximately $485,000.

Several other institutional investors and hedge funds have also bought and sold shares of KNSA. Nuveen LLC acquired a new position in shares of Kiniksa Pharmaceuticals International during the first quarter worth $16,992,000. AQR Capital Management LLC grew its stake in Kiniksa Pharmaceuticals International by 149.1% during the 1st quarter. AQR Capital Management LLC now owns 491,761 shares of the company's stock worth $10,922,000 after buying an additional 294,319 shares during the last quarter. Millennium Management LLC increased its position in Kiniksa Pharmaceuticals International by 50.9% during the 4th quarter. Millennium Management LLC now owns 779,672 shares of the company's stock valued at $15,422,000 after buying an additional 263,146 shares in the last quarter. Deutsche Bank AG raised its stake in Kiniksa Pharmaceuticals International by 177.1% in the first quarter. Deutsche Bank AG now owns 394,522 shares of the company's stock valued at $8,762,000 after buying an additional 252,125 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in Kiniksa Pharmaceuticals International in the first quarter worth about $4,663,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Stock Down 2.2%

Shares of NASDAQ:KNSA traded down $0.79 during midday trading on Tuesday, reaching $35.77. The company's stock had a trading volume of 274,228 shares, compared to its average volume of 400,652. The stock has a fifty day moving average of $32.20 and a 200 day moving average of $27.35. Kiniksa Pharmaceuticals International, plc has a twelve month low of $17.82 and a twelve month high of $37.34. The firm has a market capitalization of $2.65 billion, a PE ratio of 894.47 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. The company had revenue of $156.80 million during the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 29,325 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $32.55, for a total value of $954,528.75. Following the sale, the insider owned 57,403 shares in the company, valued at approximately $1,868,467.65. This represents a 33.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Mark Ragosa sold 18,889 shares of the firm's stock in a transaction that occurred on Monday, August 4th. The stock was sold at an average price of $32.89, for a total transaction of $621,259.21. Following the sale, the chief financial officer directly owned 27,009 shares in the company, valued at $888,326.01. The trade was a 41.15% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 544,971 shares of company stock worth $18,227,065. 53.48% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Wells Fargo & Company boosted their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 7th. Wedbush restated an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Finally, Jefferies Financial Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals International has an average rating of "Buy" and an average price target of $41.17.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.